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ABSTRACT
A research was conducted on the screening of carbamazepine-ibuprofen co-crystal 
formation using stoichiometric method via co-grinding and solvent evaporation. 
Pharmaceutical co-crystals formation have been proven useful in enhancing the 
solubility, dissolution rate, stability, and bioavailability of APIs and recognized as the 
promising alternative to improve APIs properties. Thus, the purpose of this research is 
to determine the co-crystal formation of carbamazepine-ibuprofen (CBZ-IBU) using 
stoichiometric methods. In this method, two techniques are used which are solvent 
evaporation and co-grinding by using ethanol, acetonitrile, ethyl acetate, propanol and 
formic acid as a solvent. Then, the produced crystal was characterized using differential 
scanning calorimetry (DSC) and optical microscopy. From this research, it is shown the 
morphology of the crystals obtained shows prismatic blade like (isometric) morphology 
indicated that these crystals refer to IBU confirmed by DSC results. The findings 
concluded that co-crystal was not being able to be formed via these methods of 
screening.
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ABSTRAK
Satu penyelidikan telah dijalankan untuk mengkaji saringan terhadap pembentukan ko-
kristal carbamazepine - ibuprofen (CBZ-IBU) menggunakan kaedah stoikiometri 
melalui dua teknik iaitu pengisaran dan penyejatan pelarut. Ko-kristal farmasi telah 
terbukti berkesan untuk meningkatkan keterlarutan, kestabilan, dan bioavailabiliti API 
dan diiktiraf sebagai alternatif yang boleh meningkatkan kualiti API. Oleh itu , tujuan 
kajian ini adalah untuk menentukan pembentukan ko-kristal CBZ – IBU menggunakan 
kaedah stoikiometri. Dua teknik telah digunakan iaitu penyejatan pelarut dan pengisaran 
dengan menggunakan ethanol, acetonitrile, ethyl acetate, propanol and asid formik
sebagai pelarut. Kemudian , kristal yang dihasilkan di analisa menggunakan differential 
scanning calorimetry (DSC ) dan mikroskop optik. Bentuk hablur kristal yang 
diperolehi daripada kajian ini menunjukkan bentuk seperti bilah prisma ( isometrik ). 
Bentuk hablur Kristal ini menunjukkan bahawa kristal ini merujuk kepada IBU dan 
telah disahkan oleh keputusan DSC. Kesimpulannya,  kristal tidak dapat dibentuk 
melalui kaedah saringan ini .
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11 INTRODUCTION
1.1 Motivation and statement of problem
Physiochemical properties of co-crystals are of great attention for the development of 
APIs. Pharmaceutical co-crystals become the motivation for drug development in the 
adjustment of the physiochemical properties to improve efficacy of a dosage form and 
the overall stability (Blagden et al., 2008). For most of the properties of co-crystals, 
when measured, has a value that lies between co-former and pure drug. The prior 
statement is supported by the data of melting point analysis of co-crystals, which often 
is found to be in between pure drug and co-former. From stability point of view, co-
crystals are balance with regard to storage conditions and moisture under normal 
processing (Blagden et al., 2008). 
Besides, pharmaceutical co-crystallization also can enhance the solubility of poorly 
water soluble drugs. Pharmacology activity of the API does not affect when co-
crystallized with pharmaceutically acceptable (GRAS) compounds but it can boost their 
physical properties like bioavailability and solubility (Zaworotko, 2008). Solubility of 
co-crystal product is often more than that of pure drug but less than that of co-crystal 
former. However, this is not usually the case since there has been evidence of reduced 
solubility of the co - crystal product in corresponding to the API. If solubility of the co -
crystal product is increased in corresponding to the API, intrinsic dissolution is also 
improved for co-crystals in corresponding to pure drug and vice versa. 
Over for the three decades, Carbamazepine (CBZ) has been an important antiepileptic 
drug. CBZ faces multiple challenges of oral administration for lower solubility of water 
with high quantity required for curative effect, auto induction for metabolism and 
limited bioavailability. Meanwhile, Ibuprofen (IBU) or propanoic acid is known as anti-
inflammatory drug. It is usually used as an analgesic or for the relief of fever and 
arthritis. IBU has less soluble in water. It is shown that CBZ and IBU solid compound 
faces the same problem such as having low solubility. Both of the compounds have low 
solubility in water but IBU is less soluble in comparison to the CBZ. In contrast, CBZ is 
less soluble in solvent in comparison to the IBU. 
2Therefore, IBU acts as co-former where the CBZ act as API because IBU more soluble 
in comparison to CBZ in solvent.  Solubility is important to deliver drugs to patient in 
safe and an efficient and cost effective manner. If the drug has low solubility, it will 
difficult to be absorbed from the gastrointestinal tract into the blood stream and 
influence the site of action (Junghanns & Muller, 2008). Therefore, improve solubility 
also can optimize the bioavailability.
1.2 Objectives
The following are the objectives of this research:
o This work aims to screen the CBZ-IBU co-crystal formation using 
stoichiometric method via evaporation and co-grinding.
1.3 Scope of this research
The following are the scope of this research:
i) Screening co-crystal using stoichiometric methods with different solvents.
ii) Characterization crystal produced using DSC and optical microscopy.
1.4 Organisation of this thesis
The structure of the reminder of the thesis is outlined as follow:
Chapter 2 is about literature review on the type of co-crystal, pharmaceutical co-
crystal, molecular interaction with the pharmaceutical co-crystal, the formation method 
and co-crystal characterization technique. In this section, all the relevant journals, 
technical paper and books taken from those researches will be studied and discussed.
Chapter 3 will be covered the part of experimental set up and will be explained in 
more details on methodology and operating procedures. The co-crystal formation 
method and characterization techniques used for this system are described in detail. In 
addition, in this chapter also explained the material used in this experiment.
Chapter 4 will be covered in the results and discussion of the research during the 
operation process. All the experimental result and data will be discussed in details 
which are included screening methods and characterization of crystal produced.
Chapter 5 will be discussed in the conclusion can be made for the study and 
some recommendations can be taken. Figure 1.1 shows the road map of the thesis.
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42 LITERATURE REVIEW
2.1 Overview
This chapter describes about the type of co-crystal, pharmaceutical co-crystal, molecular 
interaction with the pharmaceutical co-crystal, the formation method and co-crystal 
characterization technique.
2.2 Introduction
A co-crystal can be described as crystalline structure consists of two or more organic 
element, where the element may be atoms, ions or molecules which all elements are 
solid form at room temperature in a stoichiometric ratio. It is also involves interactions 
of non-covalent like ionic bonds, van-der Waals bonds or hydrogen bonds, in a crystal 
lattice (Shan and Zaworotko, 2008). According to Vishweshwar et al., in 2006 if one of 
the candidates is a pharmaceutically active ingredient, they are referred to as
pharmaceutical co-crystals. 
Active pharmaceutical ingredients (APIs) are usually delivered to the patient in the solid 
form as part of an acceptable quantity form (e.g., tablets, capsules, etc.). Solid form is 
the preferred state rather than amorphous because it is mainly most stable crystalline 
form of the compound (Morissette et al., 2004). There are several of different solid 
forms that APIs can exist, such as solvates, hydrates, amorphous solids, polymorphs, 
salts, and also co-crystals as shown in Figure 2.1. All of these forms show physical and 
chemical properties that can greatly impact the stability, bioavailability, solubility and 
other performance characteristics of the drug (Byrn et al., 1999).
5Figure 2-1: Possible solid form of a drug. Red, blue and green represent drug, 
water/solvent, counter ion, and co-former molecules respectively (Byrn et al., 1999)
Solvate is defined when one candidate is a liquid at room temperature but if both 
candidates are solids at room temperature; the crystals are defined as co-crystals 
(Morissette et al., 2004).  Usually, solvate crystals are unstable which lead to less 
soluble forms impact from the loss of solvent that may ahead to the amorphous phase 
crystallizing and also from the desolvation during storage. 
Salt formation is form from reaction between an acid-base of the APIs with an acidic. 
However, this approach has a limitation, which is the API must have a suitable (basic or 
acidic) ionizable site. In contrast, co-crystals offer a different access resulted by freely 
reversible with non-covalent interactions, where any API are not considered the acidic, 
basic or ionizable groups. Therefore, it could conceivably be co-crystallized. In 
addition, when salts are formed, the proton is fully transferred while, for co-crystals, 
there is no transfer or only an incomplete transfer (Aakeröy et al., 2007).
Meanwhile, polymorph is defined as a solid crystalline phase that would have the same 
compound with difference crystalline form (McCrone, 1965). Polymorphs may 
spontaneously convert to the stable form from a metastable form (unstable form) at a 
certain temperature. It also has different stabilities. In addition, they exhibit different 
solubility and melting points which impact the dissolution rate of drug. However, it is 
not usually straightforward to get a specific polymorph of a material (Bardwell et al., 
2011). Moreover, highly polymorphic compounds also present variety challenges in 
development of drug. 
6Thus, co-crystallization is become first placed approaches to physical property 
optimization rather than polymorph, solvates, and salt selection. The co-crystallization 
offers a field for enhancing the biopharmaceutical and physicochemical properties of 
APIs throughout the development of the new class of crystalline solids, called 
pharmaceutical co-crystals (Shan and Zaworotko, 2008). Over the last decade, 
pharmaceutical co-crystals also has been growing interest in the design of drug, which 
arise as a potential method for improvement of stability, bioavailability and low water 
solubility of drugs (Qiao et al., 2011).
2.3 Previous work on Pharmaceutical co-crystal
Pharmaceutical co-crystal can be described as crystalline of multi-component which 
involve the active pharmaceutical ingredient (API) with other components are called co-
former that are tied together in the crystal  lattice through non-covalent interactions 
primarily hydrogen bond (Qiao et al., 2011). Some researchers have defined co-formers 
as stabilizers in co-crystallization process (Qiao et al., 2011). Liquids and solids may 
also serve the purpose of co-crystal former (Shan and Zaworotko, 2008). However, 
when co-crystal reactant components are solids under ambient conditions has useful 
benefits over liquid or gas co-formers. Co-crystals are constructing based on crystal 
engineering with following the principal of the supramolecular synthesis. Although, 
pharmaceutical co-crystal still not commercialized for use in the market but there are 
much work has been done for formation of the co-crystal such as carbamazepine, 
indomethacin and ibuprofen. Table 2.1 represents some example of pharmaceutical co-
crystal.
Table 2-1: Example of pharmaceutical co-crystal
API Co-formers Methods References
Carbamazepine Saccharin -Cooling crystallization (Hickey et al., 2007)
Indomethacin Saccharin -Slow evaporation
-Liquid-assisted 
co-grinding
(Basavoju  et al., 2008)
Ibuprofen Nicotinamide -Slow evaporation  
-Slurry conversion
(Frederico et al., 2013)
Carbamazepine Nicotinamide -Slurry-based 
crystallization
(Gagnière et al., 2009)
72.4 Molecular interaction in co-crystal
Co-crystals are constructed based on supramolecular synthons. The term of 
supramolecular synthons is defined by Desiraju, in 1995 as a structural unit within supra 
molecules which can be connect by non-covalent interaction such as π-stacking, van der 
Waals force, hydrogen bonding, and halogen bonding. Meanwhile, Etter and Reutzel, in 
1999 added in designing most of the pharmaceutical co-crystals the hydrogen bonds 
play a great role. In addition, Dale et al., 2004 also provided the guidelines to predict 
the formation of hydrogen bonds as follows: (i) in hydrogen bond formation, all good 
proton donors usually are used; (ii) intramolecular hydrogen bonds are preferred over 
intermolecular hydrogen bonds in a six membered ring; (iii) the best proton donors and 
proton acceptors remain after form intermolecular hydrogen bonds with each other from 
intramolecular hydrogen bonds. Carbohydrates, amides, carboxylic acids, amino acids
and alcohols are the examples of pharmaceutically acceptable co-crystal formers that 
can be co-crystallize with target APIs as illustrated in Figure 2.2.
Figure 2-2: Typical hydrogen bonds utilized in crystal engineering (Qiao et al., 2011).
82.5 Physiochemical properties of co-crystal 
Physicochemical properties of co-crystals are a combination of individual properties of 
both drug and co-crystal former. These properties of a co-crystal need to be investigated 
in order to determine the performance in the marketed dosage form (Bryn et al., 1999). 
In the beginning development of drug, these properties, such as bioavailability, stability, 
melting point, and also solubility greatly important when forms a new compound, such 
as a co-crystal.
2.5.1 Melting point
The melting point is indicated by the temperature at which the solid phase achieved 
equilibrium with the liquid phase. Schultheiss and Newman, in 2009 stated co-crystal 
have melting point in between the APIs and co-formers or lower than the APIs or co-
formers. It is proving that, the APIs can be tuning through forming co-crystal.
Meanwhile, Fleischman et al., in 2003 investigated the impact of crystal packing on the 
melting point of co-crystals. It is shows that although the four co-crystals had same 
heteromeric O–H•••N hydrogen bond, it had different overall packing arrangements and 
also different melting points. 
2.5.2 Solubility
Solubility of co-crystal product is usually more than that of pure drug but less than that 
of co-former. However, the solubility of the co - crystal product can be reduced in 
comparison to the API. Intrinsic dissolution is also improved for co-crystals if the 
solubility of the co - crystal product is increased in comparison to the API, pure drug 
and vice versa. For example, Miroshnyk et al., in 2009 tried to improve the solubilities 
of two APIs, which is exemestane (EX) and megestrolacetate (MA). These samples are 
prepared from organic solutions with several particle sizes. It is shown that co-
crystallization of the EX and MA enhanced the initial dissolution rates compared with 
the original crystals. In addition, the co-crystal of EX/MAL also showed a high 
dissolution rate even with large particles.
2.5.3 Bioavailability
Bioavailability is amount of extent of the active drug and the rate that attain the 
systemic circulation (Bermajo and Alvarez, 2008).  The ultimate goal of the co - crystal 
9investigation is to enhance the bioavailability of an API. For example, animal 
bioavailability needs to analyse when preparing new forms of a compound because it is 
an important parameter but there are restricted numbers of animal bioavailability 
researches on co-crystals. A dog study based on Hickey et al., in 2007 was compared a 
1:1 of mole ratio between CBZ and saccharin co-crystallized with the marketed tablets 
of carbamazepine. It is shows the pharmacokinetic parameters obtained to be similar to 
the present marketed product. 
2.6 Analysis methods for co-crystallization
Co-crystals formation can be categorized into liquid and solid based methods. Solid-
based method for co-crystal formation such as co-grinding usually refer on the 
stoichiometric ratio of the APIs and co-former, while the liquid-based methods may can 
be either non-stoichiometric ratio (reaction crystallization and slurry) (Alhaweh et al., 
2010, Zhang et al., 2007) or stoichiometric ratio (solvent evaporation crystallization and  
spray drying) (Alhalaweh et al., 2010)
2.6.1 Solvent evaporation
In this method, the APIs and co-former are taken in an appropriate equal amount and 
dissolved in a solvent and the solution was allowed to evaporate at the room 
temperature. This solvent evaporation technique works only when different molecules 
of complimentary functional group afford hydrogen bond that are more favorable than 
each of the individual components and its tend to be thermodynamically favored 
(Jayasankar et al., 2006). There are many successful co-crystal examples were obtained 
by this method such as Indomethacin–saccharin co-crystal (Basavoju et al., 2008).
2.6.2 Cooling crystallization
Cooling crystallization method used different of temperature to achieve the 
crystallization system, which has much potential of a large scale for the co-crystals
production. Crystals produced will precipitate when the solution becomes 
supersaturated with respect to co-crystal as the temperature drops down (McNamara et 
al., 2006). For example, co-crystallization of carbamazepine and nicotinamide 
(CBZ/NCT) was studied by Gagniere et al., in 2009, which the solid phase evolution 
during the cooling co-crystallization process was monitored by an in situ video probe.
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2.6.3 Co-grinding
Co-grinding can be divided into two different techniques that is dry and liquid-assisted 
grinding. Neat grinding or dry grinding involve with mixing the APIs and co-former in 
the stoichiometric ratio and grinding them either manually, using a mortar and pestle, or 
mechanically, using a ball mill or a vibratory mill. This method needs one or both APIs 
and co-former exhibiting significant vapour pressures in the solid state (Friscic and 
Jones, 2009). Meanwhile, small amount of suitable solvent are added in the mixture 
while grinding for the liquid-assisted grinding methods. There are many kinds of 
pharmaceutical co-crystals that have been successfully synthesized by using neat 
grinding method such as Indomethacin- saccharin co-crystal (Basavoju  et al., 2008). 
2.7 Analysis characterization for co-crystal
Co-crystal characterization is also an important part in co-crystal development. There 
are many type of instrument that can be used to characterized the crystal produced such 
as optical microscopy, differential scanning calorimetry (DSC), powder X-ray 
diffraction (PXRD), scanning electron microscopy (SEM) and raman spectroscopy.
2.7.1 Optical microscopy 
The basic physicochemical crystal size at preliminary level may be evaluated by optical 
microscope using stage micrometer and eyepiece micro meter (Abramowitz et al., 
2002). It is used the fundamental system of lenses and visible light to magnify images 
of small samples or particles. The basic optical microscopes are very simple, compared 
to the modern designs which are only aim to improve resolution and sample contrast. A
micrograph was generated when the image taken from an optical microscope that 
captured by normal light-sensitive cameras (Abramowitz et al., 2002). 
2.7.2 Differential scanning calorimetry (DSC)
DSC is the most widely used technique for the thermal property testing of co-crystals. 
The differential scanning calorimetry is a characterization method based on the heat of 
reaction involved in different thermal events. In the pharmaceutical industry, the DSC is 
mostly used to obtain melting points of the API and thus, determine its purity (Oberoi et 
al., 2005). It shows there is a clear difference between the melting point of the co-
formers and the co-crystal itself when the co-crystal was analyzed. It is a technique that 
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can be used for qualitative and quantitative analysis, because the heat of the reaction is 
directly proportional to the mass quantity of the compound analyzed (Yamashita et al., 
2013). However, by being a destructive technique, the thermal events that occur with 
the material can interfere with quantitative measurements, essentially on polymorphs 
and co-crystals.
2.7.3 Powder X-ray diffraction (PXRD)
The Powder X-ray diffraction is used to determine the differences between the 
crystalline structures (Buanz et al., 2011). The presence of a new crystallographic motif 
can be distinguished using this technique, which can be a polymorph or a co-crystal 
(Croker et al., 2012). It is a non-destructive method and presents diffraction patterns 
unique for each structure. However, it is a challenging method to implement in PAT 
systems. Besides, the quantitative analysis can only be made with the internal standard 
addition method or by mixture analysis, and its data can present problems due to 
preferential orientation and different crystal granulometry, which make the quantitative 
analysis difficult to perform (Chieng et al., 2011).
2.7.4 Scanning electron scanning (SEM)
Scanning electron microscope used a high-energy beam of electrons in a raster scan 
pattern to take the images of sample. It is usually used to determine micrograph of the 
co-crystal particle size (Basavoju et al., 2008). This technique very useful especially to 
distinctive the differences in their crystal habits because it allows characterization of 
surface morphology of materials. It also offers some advantage for the characterization 
of incompatibilities of materials when SEM studies were combined with other thermal 
and spectroscopic techniques, such as FT-IR, DSC and HSM (Bikiaris et al., 2005).
2.7.5 Raman spectroscopy
Raman spectroscopy has been demonstrated to be a powerful tool for distinguishing 
isostructural phase. It is used to observe the rotational, vibrational and other low 
frequency modes in a system. Moreover, it is also an alternative method to identify 
crystalline arrays of several pharmaceutical drugs (Burley et al., 2012). In addition, it is 
a quick technique, non-destructive, presents much chemical information and lower 
detection limits when compared to XRPD and DSC (De Beer et al., 2011). However, 
12
the fluorescence phenomena can make the analysis of some samples difficult, and 
micro-Raman usually presents a small laser spot, leading to sampling problems (Shin 
and Chung, 2013).
2.8 Summary
In conclusion, from the previous study, it is shown that co-crystal formation can be 
form from stoichiometric or non-stoichiometric methods. The co-crystal produced also 
can be analysed using thermal or spectroscopic techniques. It is shows that the co-
crystallization technology can enhancing the pharmaceutical properties such as habit, 
bulk density, compressibility, solubility, melting point, variability, hygroscopy, and 
dissolution rate rather than the traditional approaches such as solid dispersion or salt 
formation.
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3 MATERIALS AND METHODS
3.1 Overview
This chapter describes the materials use and the methodology applies during this 
research. This research intends to achieve two main goals which are preparation 
procedure of CBZ-IBU co-crystal and to identify physical characteristics of CBZ-IBU 
co-crystal.
3.2 Chemicals
A chemical used for the screening were obtained from various sources namely ECA 
International Corporation (Carbamazepine 99%) and Shasun Pharmaceuticals 
(ibuprofen SN grade).
3.3 Solvents
A solvent used for the screening were obtained from various sources namely Fisher 
chemical (Acetonitrile HPLC grade, Acetone analytical reagent grade), Sigma-Aldrich 
(Propanol, Ethyl acetate, Formic acid, 99.5%) and Merck Malaysia (ethanol gradient 
grade).
3.4 Preparation of the co-crystal
3.4.1 Solvent evaporation
CBZ-IBU co-crystal was crystallized using the solvent evaporation method. A mixture 
of CBZ and IBU (1:1 mole ratio) was dissolved in a 25 ml of ethanol in 50 ml of conical 
flask and heated to 30 Cͦ in incubator shaker for 1hr. If some of the solute of CBZ and 
IBU would not dissolve after one hour, 2 ml of ethanol was added until it did so. Once 
the solute of CBZ and IBU had dissolved, another 10 ml of ethanol was added again in 
the solution. The solution was left in the incubator shaker to equilibrate for 24 hour. 
After 24 hour, solution of CBZ and IBU was withdrawn from the conical flask using a 
syringe filter to remove any impurities. The solution was filled in the 20 ml vial and 
covered with parafilm, with a few small holes was poked in it. The solution was left to 
evaporate at room temperature until the crystal appears. After the crystal appears, the 
produced crystal was filtered using the vacuum pump. The produced crystal are dried at 
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room temperature for 24 hour and kept in a vial prior to characterization using 
differential scanning calorimetry (DSC) and optical microscopy (Abd Rahim et al., 
2013). The experiment was repeated using different solvent such as propanol, ethyl 
acetate, formic acid and acetonitrile and was repeated three times for each of solvent. 
The produced crystal was characterized using differential scanning calorimetry (DSC) 
and optical microscopy.
3.4.2 Co-grinding
The co-grinding method was conducted in a dust extraction hood and manually ground 
using a mortar and pestle for 10 minutes. In dry co-grinding, 50 mg of CBZ and 40 mg 
of IBU was prepared in combination of 1:1 ratios. The CBZ and IBU was ground using 
a mortar and pestle for 10 minutes while in wet co-grinding, 2 drops of ethanol was 
added while the sample was ground (Abd Rahim et al., 2013). The wet grinding 
experiment was repeated using different solvent such as acetonitrile, formic acid, ethyl 
acetate and propanol. Each of the experiment was repeated for three times. The 
produced crystal was characterized using differential scanning calorimetry (DSC) and 
optical microscopy. 
3.5 Preparation of characterization of crystal produced
3.5.1 Differential scanning calorimetry (DSC)
The formation of co-crystal via solvent evaporation, co-grinding were characterized by 
a Thermal Advantage DSC Q1000 (TA Instrument). A sample of the crystals produced 
(about 2.5 mg) was studied under a nitrogen purge (50 ml/min) and was heated (40-
200ºC) at a scanning rate of 10 ºC/min. The sample was placed in aluminium pans and 
the lids were crimped. The melting point, heat of fusion and the onset temperature were 
obtained.
3.5.2 Optical microscopy
A Dino-eye microscope eyepiece and Carl Zeiss model microscope with series number 
of 3108016587 was used to observe the morphology of the crystal obtained from co-
crystal screening. The images were taken with 771.7x magnification and at scale 1cm 
represent 25μm. The sample of co-crystal was placed at the slide using spatula. After 
that, the slide was placed at the microscope and the sample was observed using eye-
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piece. The samples used for this measurement were taken after the samples were 
filtered.
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4 RESULTS AND DISCUSSION 
4.1 Overview
In this chapter, the findings obtained from screening study will be discussed which 
comprised of DSC and microscopy analysis.
4.2 Differential scanning calorimetry (DSC)
4.2.1 Pure component
Figure 4.1 shows a large endothermic peak (curve) at 190.75ᵒ C and a small 
endothermic peak (curve) at a range between 155-165ᵒC. Whereas Figure 4.2 shows 
only one endothermic peak at 76.33ᵒ C. These peaks were attributed to melting points of 
pure CBZ and IBU respectively. A small endothermic peak (curve) represents the 
melting point of CBZ form III. While, the large endothermic peak represents the 
melting point of CBZ form I. These two endothermic peaks (curve) represent the 
characteristics of CBZ form III (Grzesiak et al., 2003). CBZ form III is the form that 
commercially available because it is thermodynamically stable at room temperature. 
The melting points obtained from the DSC curves are similar to the values mentioned in 
the literature that is 75–78ºC (Rasenack and Muller, 2002) for the IBU while for CBZ in 
between 190-191 ºC (Wu et al., 2011). These values together with the accuracy of the 
melting peaks indicate a high purity of ibuprofen and CBZ. The melting point for pure 
CBZ and pure IBU are listed in Table 4.1. 
